Veloxis Pharmaceuticals

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCC, AbbVie, GPCR, Ulcerative colitis, Head, Alpha globulin, Survival, Data science, Data analysis, Drug discovery, Partnership, Hook effect, HNSCC, Boehringer Ingelheim, Inflammation, Patient, Research, RNA, Veloxis Pharmaceuticals, Cancer, Lung cancer, Bank statement, AACR, Investment, First, Therapy, ESMO, Collaboration, Hepatocellular carcinoma, RNA therapeutics, FDA, Artificial intelligence, Audit committee, Food, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.
  • Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: “Our business-model is mostly based on recurrent and strategic partnerships with pharmaceutical companies.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 27, 2024.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2023.

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Retrieved on: 
Friday, June 23, 2023
Florida Atlantic University, Senior, BS, Employment, Compensated emancipation, Finance, Atlantic University, Certified Public Accountant, Sale, Ernst & Young, PSO, Patient, SAN, Veloxis Pharmaceuticals, Ernst, Heron, Market for corporate control, Pleasure, Corporate finance, Growth, Therapy, Inducement, Accounting, Pharmaceutical industry, Chiesi Farmaceutici

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs,  announced today the appointment of Ira Duarte as Chief Financial Officer.

Key Points: 
  • SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs,  announced today the appointment of Ira Duarte as Chief Financial Officer.
  • "I am excited to welcome Ira to Heron as Chief Financial Officer," said Craig Collard, Chief Executive Officer of Heron.
  • Ms. Duarte brings significant experience and expertise in financial leadership to Heron.
  • Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 – 2023, most recently as Chief Financial Officer, at Veloxis Pharmaceuticals, Inc., a fully integrated specialty pharmaceutical company.

HepQuant Announces Additions to the Executive Leadership Team to Drive Commercialization

Retrieved on: 
Tuesday, June 13, 2023
Pharmaceutical, Health, Medical Devices, Intellectual property, Diagnosis, Senior, Hepatology, Marketing, Liver disease, Biotechnology, Policy, MBA, Medicine, Biomarker, Strategic planning, Doctor of Philosophy, Organization, Takeda Pharmaceutical Company, DSM-IV codes, Acquisition, MD, Patient, Risk, Nursing care plan, R, Neurology, Management, Takeda, Veloxis Pharmaceuticals

HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team.

Key Points: 
  • HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team.
  • Four seasoned executives have joined HepQuant to round out the Company’s leadership team and finalize preparations to launch its quantitative liver function test.
  • Dr. Pitts joins HepQuant with more than 20 years of business, R&D and operational leadership experience in biotechnology, biopharma, and medical diagnostics.
  • She is a diagnostics industry executive with deep experience in strategic marketing, cross-functional team management, commercialization and reimbursement strategy.

OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update

Retrieved on: 
Thursday, April 27, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Well, Real, US Foods, Disease, ICI, Hepatocellular carcinoma, IO, FOLFIRI, European Medicines Agency, ESMO, American Society of Clinical Oncology, NTB, Quality of life, Cancer, Head, Compassion, FOLFIRINOX, SOC, Lung cancer, Immunotherapy, Public Health Agency of Canada, European Society for Medical Oncology, EMA, Boehringer Ingelheim, ASCO, Investment, Patient, ISIN, Mnemos EP, FDA, OSE, IND, Society, Food, Safety, Nivolumab, Pharmaceutical industry, NSCLC, Veloxis Pharmaceuticals

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2023 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2023 Company’s outlook.
  • I strongly believe that OSE has a very exciting future and is well positioned to meet all of its key stakeholders’ expectations.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on April 27, 2023.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2022.

Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital

Retrieved on: 
Wednesday, February 22, 2023
Douglas, Heron & Company, Annual general meeting, Patient, Quart, Therapy, Pharming, Growth, SAN, Drug discovery, Veloxis Pharmaceuticals, Management, Rubric, Velan

SAN DIEGO, Feb. 22, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that it has entered into a cooperation agreement with two of its shareholders, Rubric Capital Management LP ("Rubric") and Velan Capital Investment Management LP ("Velan").  

Key Points: 
  • SAN DIEGO, Feb. 22, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that it has entered into a cooperation agreement with two of its shareholders, Rubric Capital Management LP ("Rubric") and Velan Capital Investment Management LP ("Velan").
  • Heron also announced it will separate the roles of Chairman and CEO after the conclusion of its 2023 Annual Meeting.
  • Under the terms of the cooperation agreement, Rubric and Velan have agreed to customary standstill, voting commitments and other provisions.
  • A copy of the cooperation agreement will be included in a Form 8-K filed with the U.S. Securities and Exchange Commission.

Biohope and C. Alan Foundation Named Winners of the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation

Retrieved on: 
Monday, October 17, 2022
LinkedIn, LAUNCH (Innovation Challenge), Chicago Innovation Awards, Transplant, Health care, Dialysis, Life, Ammonia, Education, Patient, Twitter, Instagram, Technology, Kidney disease, Industry, Asahi Kasei, Digital Impact Awards Africa, CEO, Organ transplantation, Innovation, EST, Conditional sentence, Solution, Pharmaceutical industry, Dentistry, Cryptocurrency, Veloxis Pharmaceuticals, CARY, Facebook

"We are encouraged and inspired by the innovation on display as a part of this Innovation Challenge," said Mark Hensley, CEO of Veloxis, an Asahi Kasei company.

Key Points: 
  • "We are encouraged and inspired by the innovation on display as a part of this Innovation Challenge," said Mark Hensley, CEO of Veloxis, an Asahi Kasei company.
  • "Each of these entrepreneurs share Veloxis' commitment to patients and we are grateful for the opportunity to support their work.
  • Congratulations to all of the finalists on their exciting future in addressing the many unmet needs that remain in transplantation."
  • Before a panel of independent judges, 10 finalists pitched solutions for transforming organ transplantation.

C-Path's Transplant Therapeutics Consortium receives EMA Draft Qualification Opinion for the iBox Scoring System

Retrieved on: 
Friday, October 14, 2022
AST, U.S. Department of Defense Strategy for Operating in Cyberspace, TTC, Health care, Therapy, European Medicines Agency, Life, Dialysis, IBox, Review, Government, SOC, EMA, Ammonia, Food and Drug Administration, Proteinuria, Banff, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IST, Patient, Drug development, Society, Standard of care, HHS, Transplant, Multimedia, Partnership, Unitary state, Food, Transplant surgeon, Asahi Kasei, CEO, Biopsy, Critical Path Institute, Office of Inspector General, U.S. Department of Health and Human Services, FDA, Solution, EGFR, Pharmaceutical industry, Dentistry, Veloxis Pharmaceuticals

CARY, N.C., Oct. 14, 2022 /PRNewswire/ -- Critical Path Institute (C-Path) announced October 13, 2022 that its Transplant Therapeutic Consortium (TTC), of which Veloxis Pharmaceuticals is a member, received a draft qualification opinion for the iBox Scoring System through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development. This significant qualification means that the iBox Scoring System, which supports the evaluation of novel immunosuppressive therapy (IST) applications with EMA, will soon be available to be used as a secondary efficacy endpoint in kidney transplant clinical trials.

Key Points: 
  • This significant qualification means that the iBox Scoring System, which supports the evaluation of novel immunosuppressive therapy (IST) applications with EMA, will soon be available to be used as a secondary efficacy endpoint in kidney transplant clinical trials.
  • The draft qualification opinion is going through a public consultation stage through Nov. 17, 2022.
  • Improving the long-term outcomes in kidney transplant recipients is the ultimate goal and, as such, the qualification of the iBox Scoring System has been TTC's primary initiative since its inception in 2017.
  • "Veloxis is proud to be a part of the Transplant Therapeutics Consortium and the incredible work to achieve draft qualification opinion status for the iBox Scoring System," says Mark Hensley, CEO of Veloxis.

Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation

Retrieved on: 
Monday, September 19, 2022
Dialysis, Organ transplantation, Twitter, MD, Justice, Conditional sentence, Creativity, LinkedIn, Population, Life, LAUNCH (Innovation Challenge), Patient, CEO, Digital Impact Awards Africa, Chicago Innovation Awards, Instagram, Solution, Doctor of Philosophy, Ammonia, Asahi Kasei, Diversity, Health care, Innovation, Transplant, Pharmaceutical industry, Facebook, CARY, Veloxis Pharmaceuticals, Equity

NEW YORK and CARY, N.C., Sept. 19, 2022 /PRNewswire/ --Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 "Transforming Organ Transplantation Through Innovation" Challenge.

Key Points: 
  • NEW YORK and CARY, N.C., Sept. 19, 2022 /PRNewswire/ --Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 "Transforming Organ Transplantation Through Innovation" Challenge.
  • "We are grateful for the opportunity to partner with Lyfebulb and are encouraged by the tremendous response to the Innovation Challenge, and the solutions our finalists have developed for this unique patient population," saysMark Hensley, CEO of Veloxis, an Asahi Kasei company.
  • "Veloxis shares their collective energy and dedication to the transplant community, as we continue to invest in solving the many unmet needs that remain in transplantation."
  • Veloxis Pharmaceuticals, Inc, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients.

Lyfebulb and Veloxis Pharmaceuticals Seek Applicants for the Global 2022 Innovation Challenge in Organ Transplantation

Retrieved on: 
Tuesday, July 26, 2022
Asahi Kasei, Conditional sentence, LAUNCH (Innovation Challenge), Health care, Diagnosis, Industry, Twitter, Instagram, CEO, Dialysis, Digital Impact Awards Africa, Solution, The Ultimate Live Experience, Chicago Innovation Awards, Patient, LinkedIn, Life, Innovation, Ammonia, Transplant, Founder, Population, Pharmaceutical industry, Dentistry, Veloxis Pharmaceuticals, CARY, Facebook

NEW YORK and CARY, N.C., July 26, 2022 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their "Transforming Organ Transplantation Through Innovation" Challenge.

Key Points: 
  • NEW YORK and CARY, N.C., July 26, 2022 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their "Transforming Organ Transplantation Through Innovation" Challenge.
  • Additionally, Veloxis Pharmaceuticals may consider possible partnerships or investment opportunities with finalists beyond the challenge.
  • "At Veloxis, we are committed to improving the lives and outcomes of transplant patients across the globe," says Mark Hensley, CEO of Veloxis.
  • Veloxis Pharmaceuticals, Inc, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients.

OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression

Retrieved on: 
Wednesday, May 18, 2022
OSE, Transplant, Pharmacokinetics, Health care, Fortification, Autoimmune disease, Immune system, Tissue, IL-7, HCC, Immunotherapy, Inflammation, Teaching hospital, Clinical trial, COVID-19, Large-cell lung carcinoma, Mnemos EP, Boehringer Ingelheim, Nivolumab, Pancreatic cancer, Mab, Growth, Asahi Kasei, GLOBE, Ulcerative colitis, Cancer, Solution, Dialysis, IV, HNSCC, Partnership, Ammonia, Hepatocellular carcinoma, Epitope, ISIN, BI, CD28, Patient, PD-1, SC, IND, Life, Safety, Pharmaceutical industry, Vaccine, Dentistry, Veloxis Pharmaceuticals, Regulatory T cell

NANTES, France, May 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.

Key Points: 
  • VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
  • VEL-101/FR104s prior Phase 1, randomized, double-blind, placebo-controlled study evaluated single and multiple ascending IV doses of VEL-101/FR104 in healthy participants.
  • The current Phase 1 study will provide important data following SC administration before proceeding to studies in the kidney transplant population.
  • We are excited to initiate the development of VEL-101 with this study in healthy participants in the United States.